Schering Corporation

Merck Sharp + Dohme Corp.

Schering-plough Corporation

Pharmacopeia Drug Discovery, Inc.

Pharmacopeia Inc.

Schering Coporation

Scheeing Corporation

Kevin D McCormick

Robert G Aslanian

Neng-Yang Shih

Christopher W Boyce

Michael Berlin

Pietro Mangiaracina

Manuel De Lera Ruiz

John J Piwinski

Pauline C Ting

Younong Yu

Junying Zheng

Mwangi W Mutahi

Stuart B Rosenblum

Daniel M Solomon

Wing C Tom

Anandan Palani

Purakkattle J Biju

Jianhua Chao

Xiao Chen

Salem Fevrier

Xianhai Huang

David J Blythin

Ho-Jane Shue

Li Dong

Ashwin Umesh Rao

Henry A Vaccaro

Jianhua Cao

Ning Shao

Jie Wu

Phieng Siliphaivanh

Rongze Kuang

Qingbei Zeng

Chia-Yu Huang

Walter Won

Bo Liang

Xiaohong Zhu

Dong Xiao

Hongjun Zhang

Joey Lee Methot

Wei Zhou

Rong-qiang Liu

Mwangi Wa Mutahi

John J Baldwin

Ashit K Ganguly

Ge Li

Ying Huang

Bandarpalle B Shankar

Robert D Mazzola, Jr

Richard J Friary

Gregory A Reichard

Yeon-Hee Lim

Qin Jiang

Jun Qin

Elizabeth Helen Kelley

Henry M Vaccaro

Rachel Nicola MacCoss

Nicholas I Carruthers

Pawan Dhondi

Ruiyan Liu

Michael P Kirkup

James M Spitler

Sylvia Joanna Degrado

Cheryl A Alaimo

William Colby Brown

Lisa Guise-Zawacki

Andrew Lupo, Jr

Jolicia Polivina Gauuan

Andrew J Leyhane

Joseph A Kozlowski

Brian Alexander McKittrick

Amjad Ali

Ronald L Wolin

Jason D Brubaker

Michael Man-Chu Lo

Joshua Close

Joon Jung

Timothy J Henderson

John P Caldwell

Tao Yu

John W Butcher

Jayaram R Tagat

Tanweer A Khan

Haiqun Tang

Yonglian Zhang

Andrew T Lupo

Heping Wu

Gang Zhou

Michelle Martinez

Joe F Lee

Jae-Hun Kim

Huagang Lu

John A Hey

Scott Peterson

Liwu Hong

Chander Shekher Celly

John C Anthes

Hongwu Yang

Yoon Joo Lee

Rema Danielle Bitar

Alexander L Tung

The present invention is directed to compounds of generic formula I: or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist. 

[object Object]

The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J, J, R, R, R, R, R, R, R, R, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction. 

The invention provides certain quinolines and aza-quinolines of the Formula (I), and their pharmaceutically acceptable salts, wherein E, J, J, J, R, R, R, R, R, R, R, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction. 

This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTHreceptor. 

The invention provides certain cycloalkyl-fused tetrahydroquinolines of the Formula (I), and their pharmaceutically acceptable salts and esters, wherein R, R, R, R, R, E, Y, Z, n, u, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction.

In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators

The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, or isomers of said compounds), having the general structure: 

C20-C21 substituted glucocorticoid receptor agonists

In its many embodiments, the present invention provides a novel class of biaryl compounds as inhibitors of &#xff;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#xff;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Functionally selective alpha2C adrenoreceptor agonists

Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators

In its many embodiments, the present invention provides a novel class of chroman compounds of formula I as &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of prepaxing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.  

Derivatives and analogs of chroman as functionally selective ALPHA2C adrenoreceptor agonists

In its many embodiments, the present invention provides a novel class of heterocyclic derivatives as a2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the a2C adrenergic receptors using such compounds or pharmaceutical compositions.

In its many embodiments, the present invention provides a novel class of biaryi spiroaminooxazoline analogues as modulators of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators

In its many embodiments, the present invention provides a novel class of naphthene- and indane-type as inhibitors of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Functionally selective ALPHA2C adrenoreceptor agonists

In its many embodiments, the present invention provides a novel class of indolines as inhibitors of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as &#x3b1;2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the &#x3b1;2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.

ALPHA2C adrenoreceptor agonists

Growing community of inventors

Basking Ridge, NJ, United States of America

Kevin D McCormick